Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Abstract Background In December 2022, the Taiwan National Health Insurance Administration (NHIA) announced the reimbursement of three dosages of pemigatinib 4.5 mg, 9 mg, and 13.5 mg for treating advanced intrahepatic cholangiocarcinoma (ICC) with fibroblast growth factor receptor 2 (FGFR2) fusions/...

Full description

Bibliographic Details
Main Authors: Zi-Rong Chen, Chen-Han Chueh, Nai-Jung Chiang, Yi-Wen Tsai
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Pemigatinib
Intrahepataic cholangiocarcinoma
Targeted therapy
Economic evaluation
Cost-effectiveness analysis
Price listing strategy
Online Access:https://doi.org/10.1186/s12962-023-00473-5

Internet

https://doi.org/10.1186/s12962-023-00473-5

Similar Items